TITLE:
Detection of Clinically Significant Warm Reactive Anti-A1 in a Post Red Blood Cells Transfusion Patient with Acute Lymphoblastic Leukemia
AUTHORS:
Ahmed Alharbi, Alenazi Abdullah Mahal, Al Saqri Faisal, Wasel Haya, Alotaibi Abdulmohsen, Hassan Jalal, Shareefi Ahmed, Almutairi Saleh, Alharbi Abrar, Almutairi Eiman, Alzabaidi Waleed, Almutariy Hiyam, Alotaibi Rayyan, Alfraidi Rawan, Alahmadi Omar, Alghamdi Abdullah, Alotaibi Sarah
KEYWORDS:
Anti-A1, Clinical Significant, Direct Antiglobulin Testing, Anti-A1 Lectine, Compatibility
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.12 No.6,
June
20,
2023
ABSTRACT: The purpose of this article is to report that some anti-A1 that react at 37°C are IgG antibodies and are clinically significant, as they can cause the destruction of a proportion of A1 cells in vivo following the transfusion of red blood cells. Therefore, when a serum of an individual contains anti-A1, further testing of the plasma against group A1, A2, and O by referencing red blood cells and individual cells against anti-A1 lectin (Dolichos biflorus lectin) must be performed. Confirming the specificity of anti-A1 by referencing red blood cells is also important in selecting the appropriate blood for transfusion. ABO antibodies are naturally occurring and activate the complement cascade, making them more likely to cause severe transfusion reactions compared to antibodies to other RBC antigens.